In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae
In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae
复制标题
DOI：
10.1016/j.ijantimicag.2020.106178
复制
发表时间：
2020-12-01
影响因子：
10.8
通讯作者：
Burgess, David S.
中科院分区：
文献类型：
--
作者：
Clark, Justin A.;Kulengowski, Brandon;Burgess, David S.
埃拉环素已被证明对革兰氏阴性菌具有广谱活性，包括碳青霉烯类耐药肠杆菌科（CRE）。我们比较了eravacycline与替加环素在从学术医学中心患者培养的CRE分离株中的活性。埃拉环素比替加环素更有效[平均最小抑菌浓度（MIC）比= 0.76，95%置信区间0.66-0.87];然而，观察到埃拉环素的MIC 90高于先前报告的4 μ g/mL。未来的研究是必要的，以阐明驱动这种差异的机制。(C)2020爱思唯尔有限公司和国际抗菌药物化学治疗学会。All rights reserved.
Eravacycline has been shown to have broad-spectrum activity against Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae (CRE). We compared the activity of eravacycline with that of tigecycline in CRE isolates cultured from patients at an academic medical centre. Eravacycline was more potent than tigecycline [mean minimum inhibitory concentration (MIC) ratio = 0.76, 95% confidence interval 0.66-0.87]; however, the MIC90 observed for eravacycline was higher than previously reported at 4 mu g/mL. Future studies are necessary to elucidate the mechanism driving this difference. (C) 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.